Fairvalue-Calculator Fairvalue-Calculator
EN DE

Onconetix, Inc (ONCO) Fair Value & Analysis

Healthcare · US · Market cap $3.4M

Price$1.00
Fair Value$2.86
Upside+186.0%
Quality95/100
Evidence: Low Range $2.14 – $4.27

Fair value as of: Jun 25, 2026

Analysis

Onconetix, Inc (ONCO) currently trades at $1.00, while our model-based Fair Value estimate is $2.86 — implying the stock looks roughly 186.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Onconetix, Inc (ONCO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.86 versus a price of $1.00 — about +186% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ONCO?
Our 21-model fair value for Onconetix, Inc is $2.86 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.00.
What is the quality score of ONCO?
Onconetix, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.